Edition:
United Kingdom

Medicines Co (MDCO.OQ)

MDCO.OQ on NASDAQ Stock Exchange Global Select Market

27.51USD
5:52pm GMT
Change (% chg)

$-0.14 (-0.51%)
Prev Close
$27.65
Open
$27.65
Day's High
$27.95
Day's Low
$27.36
Volume
126,118
Avg. Vol
405,928
52-wk High
$55.94
52-wk Low
$25.41

Latest Key Developments (Source: Significant Developments)

Melinta Therapeutics Enters Agreement To Acquire Infectious Disease Business From The Medicines Company
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Melinta Therapeutics, Inc. ::MELINTA THERAPEUTICS ENTERS INTO AGREEMENT TO ACQUIRE INFECTIOUS DISEASE BUSINESS FROM THE MEDICINES COMPANY.  Full Article

Medicines Company Announces Definitive Agreement To Sell Its Infectious Disease Business Unit To Melinta Therapeutics
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Medicines Co ::THE MEDICINES COMPANY ANNOUNCES DEFINITIVE AGREEMENT TO SELL ITS INFECTIOUS DISEASE BUSINESS UNIT TO MELINTA THERAPEUTICS.MEDICINES - TO SELL INFECTIOUS DISEASE BUSINESS UNIT TO MELINTA THERAPEUTICS FOR $270 MILLION IN UPFRONT CONSIDERATION AND GUARANTEED PAYMENTS.MEDICINES - DEAL INCLUDES TIERED ROYALTY PAYMENTS OF 5% TO 25% ON WORLDWIDE NET SALES OF VABOMERE, ORBACTIV AND MINOCIN IV, AMONG OTHER THINGS.MEDICINES CO - MELINTA TO PAY DEAL CONSIDERATION, INCLUDING $165 MILLION IN CASH, PAID AT CLOSING, MELINTA SHARES WITH A MARKET OF $55 MILLION, AMONG OTHERS.MEDICINES CO - ‍CONCURRENT WITH EXECUTION OF DEAL, CO RECEIVED BINDING COMMITMENT FROM DEERFIELD MANAGEMENT AFFILIATE.MEDICINES CO - DEERFIELD MANAGEMENT ‍AFFILIATE COMMITTED TO PROVIDE FINANCING TO MELINTA IN CONNECTION WITH DEAL,TO PROVIDE A $100 MILLION CREDIT FACILITY​.  Full Article

Medicines Co names Fred Eshelman executive chairman
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Medicines Co -:The Medicines Company names Dr. Fred Eshelman as executive chairman; appoints Geno Germano to its board of directors.Medicines Co - ‍appointed FREDRIC N. ESHELMAN, company's current chairman of board, to newly created position of executive chairman​.Medicines Co - ‍appointments are effective immediately​.  Full Article

SymBio Pharmaceuticals says arbitration against The Medicines Company
Monday, 13 Nov 2017 

Nov 13 (Reuters) - SymBio Pharmaceuticals Ltd <4582.T>:Says co initiated an arbitration against The Medicines Company (MDCO) on Oct. 11, under the rules of International Chamber of Commerce, seeking damages arising out of MDCO's repudiation of the license agreement entered into between the co and MDCO on October 5, 2015, for the exclusive rights to develop and commercialize the patient-controlled pain management drug "SyB P-1501" (or "IONSYS") in Japan.Says the co seeks damages of $82 million (about 9 billion yen).  Full Article

The Medicines Co and Alnylam Pharmaceuticals to start phase III clinical trials of inclisiran
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Medicines Co :The Medicines Company and Alnylam Pharmaceuticals announce initiation of phase III clinical trials of inclisiran.Medicines Co - ‍continues to expect that all of these trials will commence before end of 2017​.  Full Article

The Medicines Company reports third-quarter 2017 business and financial results
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Medicines Co :The Medicines Company reports third-quarter 2017 business and financial results.Q3 GAAP loss per share $0.42 from continuing operations.Q3 earnings per share view $-1.44 -- Thomson Reuters I/B/E/S.Q3 adjusted non-GAAP loss per share $1.19 from continuing operations.Says ‍operations worldwide net revenue was $16.9 million in Q3 of 2017 compared to $37.6 million in Q3 of 2016​.Medicines Co - ‍continue to expect to announce a transaction to divest infectious disease business before end of year.Medicines Co - ‍independent of ID business transaction, finalizing plans to significantly restructure remainder of Medicines Company​.Medicines Co - ‍anticipate restructuring, intended to be substantially implemented in next 45 days, will reduce headcount to less than 60 people at Co.Q3 revenue view $24.4 million -- Thomson Reuters I/B/E/S.  Full Article

China National Accord Medicines to pay FY 2016 annual div on June 20
Wednesday, 14 Jun 2017 

June 14 (Reuters) - China National Accord Medicines Co Ltd <000028.SZ> ::* Says it plans to pay FY 2016 annual div on June 20.  Full Article

The Medicines Co reports Q2 earnings per share of $2.51 from continuing operations
Wednesday, 27 Jul 2016 

The Medicines Company Reports Second : "completed divestiture of non-core cardiovascular assets" . Quarter 2016 business and financial results . Q2 earnings per share $2.51 from continuing operations . Q2 revenue $54.7 million versus $74.5 million . Q2 adjusted loss per share $0.62 from continuing operations . Q2 revenue view $41.9 million -- Thomson Reuters I/B/E/S .Q2 earnings per share view $-1.16 -- Thomson Reuters I/B/E/S.  Full Article

Medicines Co gives Federal circuit rules for Medicines Co in Angiomax litigation
Tuesday, 12 Jul 2016 

Medicines Co [MDCO.O] : Federal circuit rules for medicines company in angiomax patent litigation . Federal circuit said company's orange book patents covering Angiomax(reg) that expire in 2028 were not invalid under "on sale" bar .Federal circuit also remanded remainder of issues on appeal and cross-appeal to original federal circuit panel.  Full Article

The Medicines Company prices $350 million of convertible notes
Tuesday, 7 Jun 2016 

Medicines Co : Prices $350 million of convertible notes . Says priced its private offering of $350 million in aggregate principal amount of its convertible senior notes due 2023 . Says notes will bear interest at a rate of 2.75% per year, payable semi-annually . Expects to use portion of net proceeds of offering to repurchase approximately $220 million of its 1.375% convertible notes due 2017 . Conversion rate for notes will initially be 20.4198 shares of common stock per $1,000 principal amount . Estimates that net proceeds from offering will be approximately $339.7 million .Expects to use approximately $29.5 million of net proceeds from offering to pay cost of capped call transactions.  Full Article

Photo

GSK, other drugmakers bet on post-Brexit UK science

LONDON Britain won a vote of confidence from its economically important life sciences sector on Wednesday as several major drug companies committed to invest in the country under the government's industrial strategy plans after Brexit.